Activation of blood coagulation in cancer: Implications for tumour progression

Bioscience Reports

Volumn 33, Issue 5, 2013, Pages 701-710

  Lima, Luize G ^a,b   Monteiro, Robson Q ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Blood coagulation; Metastasis; Protease activated receptor; Tissue factor; Trousseau's syndrome; Tumour Growth

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; LUFAXIN; MUCIN; NAPC2; PCI 27483; PHOSPHATIDYLSERINE; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR;

BLOOD CLOTTING; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; MELANOMA; METASTASIS; METASTASIS INHIBITION; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; REVIEW; THROMBOPHILIA; THROMBOSIS; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; BLOOD; DISEASE COURSE; DRUG ANTAGONISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84884644419     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20130057     Document Type: Review

References (136)

1. Trousseau, A. (1865) Phlegmasia alba dolens. Clin. Med. Hotel-Dieu Paris 3, 654-712
2. Rickles, F. R. and Levine, M. N. (2001) Epidemiology of thrombosis in cancer. Acta Haematol. 106, 6-12
3. Mandala, M., Ferretti, G., Cremonesi, M., Cazzaniga, M., Curigliano, G. and Barni, S. (2003) Venous thromboembolism and cancer: new issues for an old topic. Crit. Rev. Oncol. Hematol. 48, 65-80
4. Hoffman, R., Haim, N. and Brenner, B. (2001) Cancer and thrombosis revisited. Blood Rev. 15, 61-67
5. Donati, M. B. (1995) Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb. Haemost. 74, 278-281
6. Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M. and Lyman, G. H. (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 5, 632-634
7. Rickles, F. R. and Edwards, R. L. (1983) Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62, 14-31
8. Sorensen, H. T., Mellemkjaer, L., Olsen, J. H. and Baron, J. A. (2000) Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343, 1846-1850
9. Levitan, N., Dowlati, A., Remick, S. C., Tahsildar, H. I., Sivinski, L. D., Beyth, R. and Rimm, A. A. (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78, 285-291
10. Sallah, S., Wan, J. Y., Nguyen, N. P., Hanrahan, L. R. and Sigounas, G. (2001) Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb. Haemost. 86, 828-833
11. Degen, J. L. and Palumbo, J. S. (2012) Hemostatic factors, innate immunity and malignancy. Thromb. Res. 129 (Suppl 1), S1-S5
12. van den Berg, Y. W., Osanto, S., Reitsma, P. H. and Versteeg, H. H. (2012) The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 119, 924-932
13. Francis, J. L., Biggerstaff, J. and Amirkhosravi, A. (1998) Hemostasis and malignancy. Sem. Thromb. Hemost. 24, 93-109
14. Zwicker, J. I., Furie, B. C. and Furie, B. (2007) Cancer-associated thrombosis. Crit. Rev. Oncol. Hematol. 62, 126-136
15. Ruf, W. and Edgington, T. S. (1994) Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J. 8, 385-390
16. Mueller, B. M., Reisfeld, R. A., Edgington, T. S. and Ruf, W. (1992) Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc. Natl. Acad. Sci. U.S.A. 89, 11832-11836
17. Lima, L. G., Oliveira, A. S., Campos, L. C., Bonamino, M., Chammas, R., Werneck, C., Vicente, C. P., Barcinski, M. A., Petersen, L. C. and Monteiro, R. Q. (2011) Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles. Thromb. Haemost. 106, 712-723
18. Gerotziafas, G. T., Galea, V., Mbemba, E., Khaterchi, A., Sassi, M., Baccouche, H., Prengel, C., van Dreden, P. and Hatmi, M. (2012) Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thromb. Res. 129, 779-786
19. Rak, J., Milsom, C., Magnus, N. and Yu, J. (2009) Tissue factor in tumour progression. Best Pract. Res. Clin. Haematol. 22, 71-83
20. Yu, J. L., May, L., Lhotak, V., Shahrzad, S., Shirasawa, S., Weitz, J. I., Coomber, B. L., Mackman, N. and Rak, J. W. (2005) Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105, 1734-1741
21. Milsom, C. C., Yu, J. L., Mackman, N., Micallef, J., Anderson, G. M., Guha, A. and Rak, J. W. (2008) Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res. 68, 10068-10076
22. Rong, Y., Post, D. E., Pieper, R. O., Durden, D. L., van Meir, E. G. and Brat, D. J. (2005) PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 65, 1406-1413
23. Zhang, X., Yu, H., Lou, J. R., Zheng, J., Zhu, H., Popescu, N., Lupu, F., Lind, S. E. and Ding, W. (2011) MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J. Biol. Chem. 286, 1429-1435
24. Utsugi, T., Schroit, A. J., Connor, J., Bucana, C. D. and Fidler, I. J. (1991) Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51, 3062-3066
25. Tormoen, G. W., Cianchetti, F. A., Bock, P. E. and McCarty, O. J. T. (2012) Development of coagulation factor probes for the identification of procoagulant circulating tumor cells. Front. Oncol. 2, 110
26. Tormoen, G. W., Haley, K. M., Levine, R. L. and McCarty, O. J. T. (2012) Do circulating tumor cells play a role in coagulation and thrombosis? Front. Oncol. 2, 115
27. VanDeWater, L., Tracy, P. B., Aronson, D., Mann, K. G. and Dvorak, H. F. (1985) Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res. 45, 5521-5525
28. Rickles, F. R. and Falanga, A. (2001) Molecular basis for the relationship between thrombosis and cancer. Thromb. Res. 102, V215-V224
29. Kirszberg, C., Rumjanek, V. M. and Monteiro, R. Q. (2005) Assembly and regulation of prothrombinase complex on B16F10 melanoma cells. Thromb. Res. 115, 123-129
30. Kirszberg, C., Lima, L. G., Da Silva de, O. A., Pickering, W., Gray, E., Barrowcliffe, T. W., Rumjanek, V. M. and Monteiro, R. Q. (2009) Simultaneous tissue factor expression and phosphatidylserine exposure account for the highly procoagulant pattern of melanoma cell lines. Melanoma Res. 19, 301-308
31. Fernandes, R. S., Kirszberg, C., Rumjanek, V. M. and Monteiro, R. Q. (2006) On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells. J. Thromb. Haemost. 4, 1546-1552
32. Zacharski, L. R., Dunwiddie, C., Nutt, E. M., Hunt, J. and Memoli, V. A. (1991) Cellular localization of activated factor X by Xa-specific probes. Thromb. Haemost. 65, 545-548
33. Zacharski, L. R., Memoli, V. A., Morain, W. D., Schlaeppi, J. M. and Rousseau, S. M. (1995) Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Thromb. Haemost. 73, 793-797
34. Buller, H. R., van Doormaal, F. F., van Sluis, G. L. and Kamphuisen, P. W. (2007) Cancer and thrombosis: from molecular mechanisms to clinical presentations. J. Thromb. Haemost. 5 (Suppl 1), 246-254
35. Khorana, A. A., Ahrendt, S. A., Ryan, C. K., Francis, C. W., Hruban, R. H., Hu, Y. C., Hostetter, G., Harvey, J. and Taubman, M. B. (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin. Cancer Res. 13, 2870-2875
36. Abe, K., Shoji, M., Chen, J., Bierhaus, A., Danave, I., Micko, C., Casper, K., Dillehay, D. L., Nawroth, P. P. and Rickles, F. R. (1999) Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc. Natl. Acad. Sci. U.S.A. 96, 8663-8668
37. Coughlin, S. R. (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3, 1800-1814
38. Riewald, M. and Ruf, W. (2001) Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc. Natl. Acad. Sci. U.S.A. 98, 7742-7747
39. Camerer, E., Qazi, A. A., Duong, D. N., Cornelissen, I., Advincula, R. and Coughlin, S. R. (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104, 397-401
40. Ossovskaya, V. S. and Bunnett, N. W. (2004) Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 84, 579-621
41. Henrikson, K. P., Salazar, S. L., Fenton, J. W. and Pentecost, B. T. (1999) Role of thrombin receptor in breast cancer invasiveness. Br. J. Cancer 79, 401-406
42. Ikeda, O., Egami, H., Ishiko, T., Ishikawa, S., Kamohara, H., Hidaka, H., Mita, S. and Ogawa, M. (2003) Expression of proteinase-activated receptor-2 in human pancreatic cancer: a possible relation to cancer invasion and induction of fibrosis. Int. J. Oncol. 22, 295-300
43. Yin, Y. J., Salah, Z., Grisaru-Granovsky, S., Cohen, I., Even-Ram, S. C., Maoz, M., Uziely, B., Peretz, T. and Bar-Shavit, R. (2003) Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arterioscler. Thromb. Vasc. Biol. 23, 940-944
44. Ribeiro, F. S., Simao, T. A., Amoedo, N. D., Andreollo, N. A., Lopes, L. R., Acatauassu, R., Rumjanek, F. D., Albano, R. M., Pinto, L. F. and Monteiro, R. Q. (2009) Evidence for increased expression of tissue factor and protease-activated receptor-1 in human esophageal cancer. Oncol. Rep. 21, 1599-1604
45. Veiga, C. S., Carneiro-Lobo, T. C., Coelho, C. J., Carvalho, S. M., Maia, R. C., Vasconcelos, F. C., Abdelhay, E., Mencalha, A. L., Ferreira, A. F., Castro, F. A. and Monteiro, R. Q. (2011) Increased expression of protease-activated receptor 1 (PAR-1) in human leukemias. Blood Cells Mol. Dis. 46, 230-234
46. Schaffner, F. and Ruf, W. (2008) Tissue factor and protease-activated receptor signaling in cancer. Semin. Thromb. Hemost. 34, 147-153
47. Coughlin, S. R. (2000) Thrombin signalling and protease-activated receptors. Nature 407, 258-264
48. Maragoudakis, M. E., Tsopanoglou, N. E., Andriopoulou, P. and Maragoudakis, M. M. (2000) Effects of thrombin/thrombosis in angiogenesis and tumour progression. Matrix Biol. 19, 345-351
49. Nierodzik, M. L. and Karpatkin, S. (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10, 355-362
50. Chen, J., Bierhaus, A., Schiekofer, S., Andrassy, M., Chen, B., Stern, D. M. and Nawroth, P. P. (2001) Tissue factor - a receptor involved in the control of cellular properties, including angiogenesis. Thromb. Haemost. 86, 334-345
51. Riewald, M. and Ruf, W. (2002) Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc. Med. 12, 149-154
52. Ruf, W., Dorfleutner, A. and Riewald, M. (2003) Specificity of coagulation factor signaling. J. Thromb. Haemost. 1, 1495-1503
53. Jiang, X., Bailly, M. A., Panetti, T. S., Cappello, M., Konigsberg, W. H. and Bromberg, M. E. (2004) Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J. Thromb. Haemost. 2, 93-101
54. Belting, M., Dorrell, M. I., Sandgren, S., Aguilar, E., Ahamed, J., Dorfleutner, A., Carmeliet, P., Mueller, B. M., Friedlander, M. and Ruf, W. (2004) Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat. Med. 10, 502-509
55. Hjortoe, G. M., Petersen, L. C., Albrektsen, T., Sorensen, B. B., Norby, P. L., Mandal, S. K., Pendurthi, U. R. and Rao, L. V. (2004) Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 103, 3029-3037
56. Dutra-Oliveira, A., Monteiro, R. Q. and Mariano-Oliveira, A. (2012) Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines. Biochem. Biophys. Res. Commun. 421, 221-227
57. Versteeg, H. H., Schaffner, F., Kerver, M., Petersen, H. H., Ahamed, J., Felding-Habermann, B., Takada, Y., Mueller, B. M. and Ruf, W. (2008) Inhibition of tissue factor signaling suppresses tumor growth. Blood 111, 190-199
58. Ruf, W., Disse, J., Carneiro-Lobo, T. C., Yokota, N. and Schaffner, F. (2011) Tissue factor and cell signalling in cancer progression and thrombosis. J. Thromb. Haemost. 9, 306-315
59. Albrektsen, T., Sorensen, B. B., Hjortoe, G. M., Fleckner, J., Rao, L. V. and Petersen, L. C. (2007) Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J. Thromb. Haemost. 5, 1588-1597
60. Versteeg, H. H., Schaffner, F., Kerver, M., Ellies, L. G., Andrade-Gordon, P., Mueller, B. M. and Ruf, W. (2008) Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res. 68, 7219-7227
61. Ahamed, J. and Ruf, W. (2004) Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J. Biol. Chem. 279, 23044
62. Schaffner, F., Versteeg, H. H., Schillert, A., Yokota, N., Petersen, L. C., Mueller, B. M. and Ruf, W. (2010) Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood 116, 6113
63. Ryden, L., Grabau, D., Schaffner, F., Jonsson, P. E., Ruf, W. and Belting, M. (2010) Evidence for tissue factor phosphorylation and its correlation with protease activated receptor expression and the prognosis of primary breast cancer. Int. J. Cancer 126, 2330-2340
64. Villares, G. J., Zigler, M. and Bar-Eli, M. (2011) The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis - a possible therapeutic target. Oncotarget 2, 8-17
65. Whitehead, I., Kirk, H. and Kay, R. (1995) Expression cloning of oncogenes by retroviral transfer of cDNA libraries. Mol. Cell. Biol. 15, 704-710
66. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S. and Kuliopulos, A. (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313
67. Yin, Y. J., Salah, Z., Maoz, M., Even-Ram, S. C., Ochayon, S., Neufeld, G., Katzav, S. and Bar-Shavit, R. (2003) Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB J. 17, 163-174
68. Kim, S. J., Shin, J. Y., Lee, K. D., Bae, Y. K., Choi, I. J., Park, S. H. and Chun, K. H. (2011) Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS ONE 6, e25103
69. Lee, T. H., Dásti, E., Magnus, N., Al-Nedawi, K., Meehan, B. and Rak, J. (2011) Microvesicles as mediators of intercellular communication in cancer - the emerging science of cellular 'debris'. Semin. Immunopathol. 33, 455-467
70. Zwaal, R. F. and Schroit, A. J. (1997) Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89, 1121-1132
71. Diamant, M., Tushuizen, M. E., Sturk, A. and Nieuwland, R. (2004) Cellular microparticles: new players in the field of vascular disease? Eur. J. Clin. Invest. 34, 392-401
72. Aharon, A. and Brenner, B. (2009) Microparticles, thrombosis and cancer. Best Pract. Res. Clin. Haematol. 22, 61-69
73. Dvorak, H. F., Quay, S. C., Orenstein, N. S., Dvorak, A. M., Hahn, P., Bitzer, A. M. and Carvalho, A. C. (1981) Tumor shedding and coagulation. Science 212, 923-924
74. Janowska-Wieczorek, A., Wysoczynski, M., Kijowski, J., Marquez-Curtis, L., Machalinski, B., Ratajczak, J. and Ratajczak, M. Z. (2005) Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 113, 752-760
75. Lima, L. G., Chammas, R., Monteiro, R. Q., Moreira, M. E. and Barcinski, M. A. (2009) Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Lett. 283, 168-175
76. Bastida, E., Ordinas, A., Escolar, G. and Jamieson, G. A. (1984) Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 64, 177-184
77. Yu, J. L. and Rak, J. W. (2004) Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J. Thromb. Haemost. 2, 2065-2067
78. Dvorak, H. F., Van, D. L., Bitzer, A. M., Dvorak, A. M., Anderson, D., Harvey, V. S., Bach, R., Davis, G. L., DeWolf, W. and Carvalho, A. C. (1983) Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res. 43, 4434-4442
79. Satta, N., Toti, F., Feugeas, O., Bohbot, A., Dachary-Prigent, J., Eschwege, V., Hedman, H. and Freyssinet, J. M. (1994) Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J. Immunol. 153, 3245-3255
80. McGregor, L., Martin, J. and McGregor, J. L. (2006) Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodelling and thrombosis. Front. Biosci. 11, 830-837
81. Thomas, G. M., Panicot-Dubois, L., Lacroix, R., Dignat-George, F., Lombardo, D. and Dubois, C. (2009) Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J. Exp. Med. 206, 1913-1927
82. Rauch, U., Bonderman, D., Bohrmann, B., Badimon, J. J., Himber, J., Riederer, M. A. and Nemerson, Y. (2000) Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 96, 170-175
83. Eilertsen, K. E. and Osterud, B. (2004) Tissue factor: (patho)physiology and cellular biology. Blood Coagul. Fibrinolysis 15, 521-538
84. Davila, M., Amirkhosravi, A., Coll, E., Desai, H., Robles, L., Colon, J., Baker, C. H. and Francis, J. L. (2008) Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J. Thromb. Haemost. 6, 1517-1524
85. Wang, J. G., Geddings, J. E., Aleman, M. M., Cardenas, J. C., Chantrathammachart, P., Williams, J. C., Kirchhofer, D., Bogdanov, V. Y., Bach, R. R., Rak, J. et al. (2012) Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 119, 5543-5552
86. Hron, G., Kollars, M., Weber, H., Sagaster, V., Quehenberger, P., Eichinger, S., Kyrle, P. A. and Weltermann, A. (2007) Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb. Haemost. 97, 119-123
87. Tesselaar, M. E., Romijn, F. P., van der Linden, I. K., Prins, F. A., Bertina, R. M. and Osanto, S. (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J. Thromb. Haemost. 5, 520-527
88. Langer, F., Spath, B., Haubold, K., Holstein, K., Marx, G., Wierecky, J., Brummendorf, T. H., Dierlamm, J., Bokemeyer, C. and Eifrig, B. (2008) Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann. Hematol. 87, 451-457
89. Zwicker, J. I., Liebman, H. A., Neuberg, D., Lacroix, R., Bauer, K. A., Furie, B. C. and Furie, B. (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer Res. 15, 6830-6840
90. Khan, I., Zucker-Franklin, D. and Karpatkin, S. (1975) Microthrombocytosis and platelet fragmentation associated with idiopathic/autoimmune thrombocytopenic purpura. Br. J. Haematol. 31, 449-460
91. Mallat, Z., Benamer, H., Hugel, B., Benessiano, J., Steg, P. G., Freyssinet, J. M. and Tedgui, A. (2000) Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 101, 841-843
92. Ando, M., Iwata, A., Ozeki, Y., Tsuchiya, K., Akiba, T. and Nihei, H. (2002) Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int. 62, 1757-1763
93. Rautou, P. E. and Mackman, N. (2013) Microvesicles as risk markers for venous thrombosis. Expert Rev. Hematol. 6, 91-101
94. Gemmell, C. H., Sefton, M. V. and Yeo, E. L. (1993) Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J. Biol. Chem. 268, 14586-14589
95. Castaman, G., Yu-Feng, L., Battistin, E. and Rodeghiero, F. (1997) Characterization of a novel bleeding disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle generation. Br. J. Haematol. 96, 458-463
96. Min, K. W., Gyorkey, F. and Sato, C. (1980) Mucin-producing adenocarcinomas and nonbacterial thrombotic endocarditis: pathogenetic role of tumor mucin. Cancer 45, 2374-2382
97. Varki, A. (2007) Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110, 1723-1729
98. Wahrenbrock, M., Borsig, L., Le, D., Varki, N. and Varki, A. (2003) Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J. Clin. Invest. 112, 853-862
99. Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M. and Varki, A. (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. U.S.A. 98, 3352-3357
100. Shao, B., Wahrenbrock, M. G., Yao, L., David, T., Coughlin, S. R., Xia, L., Varki, A. and McEver, R. P. (2011) Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood 118, 4015-4023
101. Demers, M., Krause, D. S., Schatzberg, D., Martinod, K., Voorhees, J. R., Fuchs, T. A., Scadden, D. T. and Wagner, D. D. (2012) Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci. U.S.A. 109, 13076-13081
102. Nitori, N., Ino, Y., Nakanishi, Y., Yamada, T., Honda, K., Yanagihara, K., Kosuge, T., Kanai, Y., Kitajima, M. and Hirohashi, S. (2005) Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 11, 2531-2539
103. Patry, G., Hovington, H., Larue, H., Harel, F., Fradet, Y. and Lacombe, L. (2008) Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer. Int. J. Cancer 122, 1592-1597
104. Sawada, M., Miyake, S., Ohdama, S., Matsubara, O., Masuda, S., Yakumaru, K. and Yoshizawa, Y. (1999) Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br. J. Cancer 79, 472-477
105. Nakasaki, T., Wada, H., Shigemori, C., Miki, C., Gabazza, E. C., Nobori, T., Nakamura, S. and Shiku, H. (2002) Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am. J. Hematol. 69, 247-254
106. Poon, R. T., Lau, C. P., Ho, J. W., Yu, W. C., Fan, S. T. and Wong, J. (2003) Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin. Cancer Res. 9, 5339-5345
107. Zhang, Y., Deng, Y., Luther, T., Muller, M., Ziegler, R., Waldherr, R., Stern, D. M. and Nawroth, P. P. (1994) Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J. Clin. Invest. 94, 1320-1327
108. Rak, J., Milsom, C., May, L., Klement, P. and Yu, J. (2006) Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin. Thromb. Hemost. 32, 54-70
109. Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, K. W., Hu, Z., Barney, K. A. and Degen, J. L. (2007) Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 110, 133-141
110. Palumbo, J. S. and Degen, J. L. (2007) Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb. Res. 120 (Suppl 2), S22-S28
111. Palumbo, J. S., Barney, K. A., Blevins, E. A., Shaw, M. A., Mishra, A., Flick, M. J., Kombrinck, K. W., Talmage, K. E., Souri, M., Ichinose, A. and Degen, J. L. (2008) Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J. Thromb. Haemost. 6, 812-819
112. Langer, F., Amirkhosravi, A., Ingersoll, S. B., Walker, J. M., Spath, B., Eifrig, B., Bokemeyer, C. and Francis, J. L. (2006) Experimental metastasis and primary tumor growth in mice with hemophilia A. J. Thromb. Haemost. 4, 1056-1062
113. Im, J. H., Fu, W., Wang, H., Bhatia, S. K., Hammer, D. A., Kowalska, M. A. and Muschel, R. J. (2004) Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 64, 8613-8619
114. Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, K. W., Jirouskova, M. and Degen, J. L. (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105, 178-185
115. Gil-Bernabé, A. M., Ferjancic, S., Tlalka, M., Zhao, L., Allen, P. D., Im, J. H., Watson, K., Hill, S. A., Amirkhosravi, A., Francis, J. L. et al. (2012) Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 119, 3164-3175
116. Nierodzik, M. L., Chen, K., Takeshita, K., Li, J. J., Huang, Y. Q., Feng, X. S., Dándrea, M. R., Andrade-Gordon, P. and Karpatkin, S. (1998) Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 92, 3694-3700
117. Bromberg, M. E., Bailly, M. A. and Konigsberg, W. H. (2001) Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor. Thromb. Haemost. 86, 1210-1214
118. Morris, D. R., Ding, Y., Ricks, T. K., Gullapalli, A., Wolfe, B. L. and Trejo, J. (2006) Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res. 66, 307-314
119. Su, S., Li, Y., Luo, Y., Sheng, Y., Su, Y., Padia, R. N., Pan, Z. K., Dong, Z. and Huang, S. (2009) Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene 28, 3047-3057
120. Esumi, N., Fan, D. and Fidler, I. J. (1991) Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res. 51, 4549-4556
121. Hembrough, T. A., Swartz, G. M., Papathanassiu, A., Vlasuk, G. P., Rote, W. E., Green, S. J. and Pribluda, V. S. (2003) Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 63, 2997-3000
122. Donnelly, K. M., Bromberg, M. E., Milstone, A., Madison McNiff, J. M., Terwilliger, G., Konigsberg, W. H. and Cappello, M. (1998) Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro. Thromb. Haemost. 79, 1041-1047
123. Francischetti, I. M., Valenzuela, J. G., Andersen, J. F., Mather, T. N. and Ribeiro, J. M. (2002) Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 99, 3602-3612
124. Monteiro, R. Q., Rezaie, A. R., Ribeiro, J. M. and Francischetti, I. M. (2005) Ixolaris: a factor Xa heparin-binding exosite inhibitor. Biochem. J. 387, 871-877
125. Monteiro, R. Q., Rezaie, A. R., Bae, J. S., Calvo, E., Andersen, J. F. and Francischetti, I. M. (2008) Ixolaris binding to factor X reveals a precursor state of factor Xa heparin-binding exosite. Protein Sci. 17, 146-153
126. Nazareth, R. A., Tomaz, L. S., Ortiz-Costa, S., Atella, G. C., Ribeiro, J. M., Francischetti, I. M. and Monteiro, R. Q. (2006) Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade. Thromb. Haemost. 96, 7-13
127. Carneiro-Lobo, T. C., Konig, S., Machado, D. E., Nasciutti, L. E., Forni, M. F., Francischetti, I. M., Sogayar, M. C. and Monteiro, R. Q. (2009) Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J. Thromb. Haemost. 7, 1855-1864
128. de Oliveira, A. S., Lima, L. G., Mariano-Oliveira, A., Machado, D. E., Nasciutti, L. E., Andersen, J. F., Petersen, L. C., Francischetti, I. M. and Monteiro, R. Q. (2012) Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma. Thromb. Res. 130, e163-e170
129. Carneiro-Lobo, T. C., Schaffner, F., Disse, J., Ostergaard, H., Francischetti, I. M., Monteiro, R. Q. and Ruf, W. (2012) The tick-derived inhibitor Ixolaris prevents tissue factor signaling on tumor cells. J. Thromb. Haemost. 10, 1849-1858
130. Monteiro, R. Q., Andersen, J. F. and Francischetti, I. M. B. (2011) Hematophagy and inhibition of the extrinsic and intrinsic tenase complexes. In: Toxins and Hemostasis. pp. 219-237. Springer, Netherlands
131. Springer, Netherlands 131 Zhao, J., Aguilar, G., Palencia, S., Newton, E. and Abo, A. (2009) rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin. Cancer Res. 15, 208-216
132. National Institutes of Health (2007), Safety study of recombinant NAPc2 to prevent tumor progression and metastases in metastatic colon cancer. No. NCT00443573, National Institutes of Health Clinical Center Bethesda, MD (www.ClinicalTrials.gov)
133. National Institutes of Health (2009), Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine. No. NCT01020006, National Institutes of Health Clinical Center Bethesda, MD (www.ClinicalTrials.gov)
134. Collin, N., Assumpçao, T. C., Mizurini, D. M., Gilmore, D. C., Dutra-Oliveira, A., Kotsyfakis, M., Sá-Nunes, A., Teixeira, C., Ribeiro, J. M., Monteiro, R. Q. et al. (2012) Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly Lutzomya longipalpis blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo. Arterioscler. Thromb. Vasc. Biol. 32, 2185-2198
135. Trujillo-Santos, J., Nieto, J. A., Ruíz-Gamietea, A., López-Jiménez, L., García-Bragado, F., Quintavalla, R., Monreal, M. and RIETE, Investigators (2010) Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb. Res. 125 (Suppl 2), S58-S61
136. Prandoni, P., Lensing, A. W., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M. H., Noventa, F. and Girolami, A. (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100, 3484-3488